Correlation Between Peripheral Blood Biomarkers and Immune Checkpoint Inhibitors in Treatment of Advanced Esophageal Cancer

WANG Peiwei; WENG Yiming; CUI Xue; PENG Min

doi:10.3971/j.issn.1000-8578.2023.22.0695

Cancer Research on Prevention and Treatment > 2023 > 50(1): 58-62. > DOI: 10.3971/j.issn.1000-8578.2023.22.0695

WANG Peiwei, WENG Yiming, CUI Xue, PENG Min. Correlation Between Peripheral Blood Biomarkers and Immune Checkpoint Inhibitors in Treatment of Advanced Esophageal Cancer[J]. Cancer Research on Prevention and Treatment, 2023, 50(1): 58-62. DOI: 10.3971/j.issn.1000-8578.2023.22.0695

Citation:

PDF (826 KB)

Correlation Between Peripheral Blood Biomarkers and Immune Checkpoint Inhibitors in Treatment of Advanced Esophageal Cancer

Cancer Center, Renmin Hospital of Wuhan University, Wuhan 430060, China

More Information

Corresponding author:
PENG Min, E-mail: mpeng320@whu.edu.cn
Received Date: June 20, 2022
Revised Date: October 30, 2022
Available Online: January 12, 2024

Graphical Abstract

Abstract

Abstract

Objective
To explore the effect of peripheral blood markers on the efficacy and prognosis of patients with advanced esophageal cancer treated with immune checkpoint inhibitors (ICIs).
Methods
The case data of 61 patients with advanced esophageal cancer who met the inclusion criteria were collected. Data on clinical indicators and peripheral blood markers as well as objective response rate (ORR) and progression-free-survival (PFS) were obtained.
Results
The median PFS of the included patients was 7.10 months (95%CI: 5.12-9.07). The ORR of patients with baseline lactate dehydrogenase (LDH) < 201 was better than that of patients with LDH≥201 (P < 0.05). Univariate analysis showed that baseline LDH0 < 201, neutrophil to lymphocyte ratio (NLR) < 3.9, platelet-to-lymphocyte ratio (PLR) < 240.3, and LDH1 < 249.0 two weeks after ICI treatment were significantly associated with significant improvement in PFS (P < 0.05). In multivariate analysis, patients with NLR0 < 3.9 had longer PFS (P < 0.05).
Conclusion
LDH0 < 201, NLR0 < 3.9, PLR0 < 240.3, and LDH1 < 249.0 are positively correlated with the prognosis of patients with advanced esophageal cancer treated with ICIs.
- Peripheral blood biomarkers,
- Esophageal cancer,
- Immune checkpoint inhibitors,
- Prediction,
- Efficacy

FullText(HTML)

Competing interests: The authors declare that they have no competing interests.

References (26)

References

[1]	Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249. doi: 10.3322/caac.21660
[2]	Allaire JC, Balk M, Azmi S, et al. Use of PD-1 and PD-L1 inhibitors after first-line therapy in esophageal cancer patients in the US[J]. Curr Med Res Opin, 2021, 37(8): 1403-1407. doi: 10.1080/03007995.2021.1929134
[3]	Janjigian YY, Shitara K, Moehler M, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial[J]. Lancet, 2021, 398(10294): 27-40. doi: 10.1016/S0140-6736(21)00797-2
[4]	Magbanua MJM, Swigart LB, Wu HT, et al. Circulating tumor DNA in neoadjuvant-treated breast cancer reflects response and survival[J]. Ann Oncol, 2021, 32(2): 229-239. doi: 10.1016/j.annonc.2020.11.007
[5]	Bartlett EK, Flynn JR, Panageas KS, et al. High neutrophil-to-lymphocyte ratio (NLR) is associated with treatment failure and death in patients who have melanoma treated with PD-1 inhibitor monotherapy[J]. Cancer, 2020, 126(1): 76-85. doi: 10.1002/cncr.32506
[6]	Russo A, Russano M, Franchina T, et al. Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR), and Outcomes with Nivolumab in Pretreated Non-Small Cell Lung Cancer (NSCLC): A Large Retrospective Multicenter Study[J]. Adv Ther, 2020, 37(3): 1145-1155. doi: 10.1007/s12325-020-01229-w
[7]	柯萍, 江波, 何文杰, 等. 外周血生物标志物与PD-1/PD-L1抑制剂治疗肺癌疗效的相关性[J]. 肿瘤防治研究, 2021, 48(11): 1006-1011. doi: 10.3971/j.issn.1000-8578.2021.21.0357 Ke P, Jiang B, He WJ, et al. Correlation Between Peripheral Blood Biomarkers and Efficacy of PD-1/PD-L1 Inhibitors Treatment on Lung Cancer[J]. Zhong Liu Fang Zhi Yan Jiu, 2021, 48(11): 1006-1011. doi: 10.3971/j.issn.1000-8578.2021.21.0357
[8]	Simonaggio A, Elaidi R, Fournier L, et al. Variation in neutrophil to lymphocyte ratio (NLR) as predictor of outcomes in metastatic renal cell carcinoma (mRCC) and non-small cell lung cancer (mNSCLC) patients treated with nivolumab[J]. Cancer Immunol Immunother, 2020, 69(12): 2513-2522. doi: 10.1007/s00262-020-02637-1
[9]	Kim H, Kwon HJ, Park SY, et al. Clinicopathological analysis and prognostic significance of programmed cell death-ligand 1 protein and mRNA expression in non-small cell lung cancer[J]. PLoS One, 2018, 13(6): e0198634. doi: 10.1371/journal.pone.0198634
[10]	Moretto R, Elliott A, Zhang J, et al. Homologous Recombination Deficiency Alterations in Colorectal Cancer: Clinical, Molecular, and Prognostic Implications[J]. J Natl Cancer Inst, 2022, 114(2): 271-279. doi: 10.1093/jnci/djab169
[11]	Diem S, Schmid S, Krapf M, et al. Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab[J]. Lung Cancer, 2017, 111: 176-181. doi: 10.1016/j.lungcan.2017.07.024
[12]	Murakami Y, Saito H, Shimizu S, et al. Neutrophil-to-Lymphocyte Ratio as a Prognostic Indicator in Patients With Unresectable Gastric Cancer[J]. Anticancer Res, 2019, 39(5): 2583-2589. doi: 10.21873/anticanres.13381
[13]	Hernando-Calvo A, García-Alvarez A, Villacampa G, et al. Dynamics of clinical biomarkers as predictors of immunotherapy benefit in metastatic melanoma patients[J]. Clin Transl Oncol, 2021, 23(2): 311-317. doi: 10.1007/s12094-020-02420-9
[14]	Pu D, Xu Q, Zhou LY, et al. Inflammation-nutritional markers of peripheral blood could predict survival in advanced non-small-cell lung cancer patients treated with PD-1 inhibitors[J]. Thorac Cancer, 2021, 12(21): 2914-2923. doi: 10.1111/1759-7714.14152
[15]	Galdiero MR, Marone G, Mantovani A. Cancer Inflammation and Cytokines[J]. Cold Spring Harb Perspect Biol, 2018, 10(8): a028662. doi: 10.1101/cshperspect.a028662
[16]	Teijeira A, Garasa S, Ochoa MC, et al. IL8, Neutrophils, and NETs in a Collusion against Cancer Immunity and Immunotherapy[J]. Clin Cancer Res, 2021, 27(9): 2383-2393. doi: 10.1158/1078-0432.CCR-20-1319
[17]	Swierczak A, Mouchemore KA, Hamilton JA, et al. Neutrophils: important contributors to tumor progression and metastasis[J]. Cancer Metastasis Rev, 2015, 34(4): 735-751. doi: 10.1007/s10555-015-9594-9
[18]	Hagerling C, Werb Z. Neutrophils: Critical components in experimental animal models of cancer[J]. Semin Immunol, 2016, 28(2): 197-204. doi: 10.1016/j.smim.2016.02.003
[19]	Suzuki R, Wei X, Allen PK, et al. Prognostic Significance of Total Lymphocyte Count, Neutrophil-to-lymphocyte Ratio, and Platelet-to-lymphocyte Ratio in Limited-stage Small-cell Lung Cancer[J]. Clin Lung Cancer, 2019, 20(2): 117-123. doi: 10.1016/j.cllc.2018.11.013
[20]	Wang H, Zhao J, Zhang M, et al. The combination of plasma fibrinogen and neutrophil lymphocyte ratio (F-NLR) is a predictive factor in patients with resectable non small cell lung cancer[J]. J Cell Physiol, 2018, 233(5): 4216-4224. doi: 10.1002/jcp.26239
[21]	Schlesinger M. Role of platelets and platelet receptors in cancer metastasis[J]. J Hematol Oncol, 2018, 11(1): 125.
[22]	Palacios-Acedo AL, Mège D, Crescence L, et al. Platelets, Thrombo-Inflammation, and Cancer: Collaborating With the Enemy[J]. Front Immunol, 2019, 10: 1805. doi: 10.3389/fimmu.2019.01805
[23]	Manerba M, Di Ianni L, Govoni M, et al. LDH inhibition impacts on heat shock response and induces senescence of hepatocellular carcinoma cells[J]. Eur J Pharm Sci, 2017, 105: 91-98.
[24]	Egenvall M, Karlsson E, Nygren-Bonnier M, et al. Associations between a composite score of hemoglobin, CRP and albumin and physical performance in older patients undergoing gastrointestinal cancer surgery[J]. Clin Nutr ESPEN, 2021, 46: 330-335.
[25]	Yamamoto T, Kawada K, Hida K, et al. Combination of lymphocyte count and albumin concentration as a new prognostic biomarker for rectal cancer[J]. Sci Rep, 2021, 11(1): 5027.
[26]	Ouyang X, Dang Y, Zhang F, et al. Low Serum Albumin Correlates with Poor Survival in Gastric Cancer Patients[J]. Clin Lab, 2018, 64(3): 239-245.

Cited By

Cited by

Periodical cited type(1)

朱翩, 杨凡, 周浪. 多模态MRI在前列腺癌疗效评价中的应用. 中国CT和MRI杂志. 2025(07)

Other cited types(1)

Figures(2) / Tables(3)

Get Citation

PDF

XML

Article views (1938) PDF downloads (643) Cited by(2)

Turn off MathJax

Article Contents

Abstract

References

Correlation Between Peripheral Blood Biomarkers and Immune Checkpoint Inhibitors in Treatment of Advanced Esophageal Cancer